DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05153590

Completed

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Weight Loss and Treatment Patterns in a Real World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland

Lead sponsor

Novo Nordisk A/S

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

269

actual

Study population

Obesity / overweight

Key I/E criterion

•BMI ≥35

Primary endpoint

•≥5% weight-loss responders

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05153590
Org study IDNN8022-4823
Secondary IDU1111-1263-5715World Health Organization (WHO)

Timeline

Milestones

Study start2021-12-03actual
Study first posted2021-12-10actual
Primary completion2022-04-15actual
Study completion2022-04-15actual
Last update posted2022-11-17actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age74 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

The study population will consist of male or female adults who have been prescribed Saxenda® for weight management in 2 cohorts reimbursed and non reimbursed

Inclusion criteria

•Signed consent (general consent for research or study-specific informed consent) obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
•Male or female, aged 18 to 74 years (both inclusive) at the time of Saxenda® initiation.
•Have been prescribed Saxenda® for weight management.
•For the reimbursed cohort, per the Swiss reimbursement criteria: BMI greater than or equal to 35 kg/m^2 or a BMIgreater than or equal to 28 and below 35 kg/m^2 with additional weight related comorbidities (pre diabetes or T2D (Type 2 Diabetes Mellitus), hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
•For the non-reimbursed cohort, BMI greater than or equal to 30 kg/m^2 or a BMI greater than or equal to 28 kg/m^2 with additional weight related comorbidities (pre diabetes or T2D, arterial hypertension, dyslipidaemia), prior to receiving the Saxenda® treatment.
•The decision to initiate treatment with commercially available Saxenda® has been made by the patient/legally acceptable representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
•Baseline weight measurement within 3 months of Saxenda® initiation/prescription.
•At least one weight assessment post-Saxenda® initiation/prescription.

Exclusion criteria

•Previous participation in this study. Participation is defined as having given informed consent in this study.
•Treatment with any investigational drug within 30 days of Saxenda® prescription/initiation.
•Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
•Concomitant treatment of Saxenda® with other GLP 1 (Glucagon-like peptide-1) receptor agonists, or orlistat.
•Concomitant treatment with sodium/glucose cotransporter-2 inhibitors (SGLT 2i), dipeptidyl peptidase-4 (DPP 4i), or insulin for the reimbursed cohort only.
•Patients who have been treated with any obesity medication for last 12 weeks prior to initiation of Saxenda® treatment.
•Patients who have previously been treated with a GLP 1 receptor agonist for the reimbursed cohort only.
•Patients who have undergone bariatric surgery at any time before starting Saxenda® treatment.
•Patients initiating Saxenda® treatment after 31 October 2020.

Endpoints (19)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
8
Safety / tolerability / PK
7
Other clinical outcomes
2
Other (unclassified)
2

Weight & body composition

8 endpoints
Primary/protocol endpoint

Relative change in body weight greater than or equal to 5% (lower BMI with weight related comorbidities) or greater than or equal to 7% (higher BMI) in reimbursed setting (yes/no)

Time frame:From Baseline (Week 0) to Week 16

≥5% weight-loss responders

threshold achievement, improvement

Primary/protocol endpoint

Relative change in body weight greater than or equal to 5%, conditionally to relative change greater than or equal to 5% or greater than or equal to 7% at Week 16 in reimbursed setting(yes/no)

Time frame:From Week 16 to Month 10

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Reimbursed setting: Absolute change in body weight

Time frame:From Baseline (Week 0) to Week 16

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Reimbursed setting: Relative change in body weight

Time frame:From Baseline (Week 0) to Week 16

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Reimbursed setting: Absolute change in body weight

Time frame:From Week 16 to Month 10

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Reimbursed setting: Relative change in body weight

Time frame:From Week 16 to Month 10

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Reimbursed setting: Absolute change in body weight

Time frame:From Baseline (Week 0) to Month 10

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Reimbursed setting: Relative change in body weight

Time frame:From Baseline (Week 0) to Month 10

Body weight, % change

percent change from baseline, improvement

Safety / tolerability / PK

7 endpoints
Secondary/protocol endpoint

Reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Baseline (Week 0) to Week 16

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Week 16 to Month 10

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Baseline (Week 0) to Month 10

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Non-reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Baseline (Week 0) to Week 16

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Non-reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Week 16 to Month 10

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Non-reimbursed setting:Discontinuation of patient (yes/no)

Time frame:From Baseline (Week 0) to Month 10

Discontinuation due to AE

categorical status, event

Secondary/protocol endpoint

Non-reimbursed setting: Discontinuation of patient (yes/no)

Time frame:From Baseline (Week 0) to end of study date

Discontinuation due to AE

categorical status, event

Other clinical outcomes

2 endpoints
Secondary/protocol endpoint/low confidence

Reimbursed setting: Presence of obesity-related comorbidities identified by authorities (*pre-diabetes, type 2 diabetes, dyslipidaemia and hypertension)

Time frame:Baseline

categorical status, descriptive

componentsT2DM prevention, LDL-C, change, Systolic BP, change

Secondary/protocol endpoint/low confidence

Non-reimbursed setting: Presence of obesity-related comorbidities identified by the authorities (pre-diabetes, type 2 diabetes, dyslipidaemia and hypertension)

Time frame:Baseline

categorical status, descriptive

componentsT2DM prevention, HbA1c <5.7% achievement, LDL-C, change, Triglycerides, change, Systolic BP, change

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Reimbursed setting: Time on Saxenda®

Time frame:From Baseline (Week 0) to end of study date

descriptive

Secondary/protocol endpoint/low confidence

Non-reimbursed setting: Time on Saxenda®

Time frame:From Baseline (Week 0) to end of study date

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.